Abstract
Endothelial dysfunction due to reduced bioavailability of nitric oxide (NO) is an early step in the course of atherosclerotic cardiovascular disease. NO is synthesized from L-arginine via the action of NO synthase, which is known to be blocked by endogenous L-arginine analogues such as asymmetric dimethylarginine (ADMA). ADMA is a naturally occurring amino acid found in plasma and various types of tissues. Plasma level of ADMA is reported to be associated with cardiovascular risk factors such as chronic kidney disease (CKD), being a strong predictor for cardiovascular disease and the progression of renal dysfunction in these patients. In this review, we discuss the molecular mechanisms for the elevation of ADMA levels in CKD. We also review here the pathological role for ADMA in cardiovascular complications in patients with CKD.
Keywords: ADMA, CKD, cardiovascular risk, dimethylarginine, dimethylarginine dimethylaminohydrolase, oxidative stress, NO
Current Enzyme Inhibition
Title: Role of Asymmetric Dimethylarginine (ADMA) in Chronic Kidney Disease
Volume: 3 Issue: 4
Author(s): Seiji Ueda, Sho-ichi Yamagishi, Yuriko Matsumoto and Seiya Okuda
Affiliation:
Keywords: ADMA, CKD, cardiovascular risk, dimethylarginine, dimethylarginine dimethylaminohydrolase, oxidative stress, NO
Abstract: Endothelial dysfunction due to reduced bioavailability of nitric oxide (NO) is an early step in the course of atherosclerotic cardiovascular disease. NO is synthesized from L-arginine via the action of NO synthase, which is known to be blocked by endogenous L-arginine analogues such as asymmetric dimethylarginine (ADMA). ADMA is a naturally occurring amino acid found in plasma and various types of tissues. Plasma level of ADMA is reported to be associated with cardiovascular risk factors such as chronic kidney disease (CKD), being a strong predictor for cardiovascular disease and the progression of renal dysfunction in these patients. In this review, we discuss the molecular mechanisms for the elevation of ADMA levels in CKD. We also review here the pathological role for ADMA in cardiovascular complications in patients with CKD.
Export Options
About this article
Cite this article as:
Ueda Seiji, Yamagishi Sho-ichi, Matsumoto Yuriko and Okuda Seiya, Role of Asymmetric Dimethylarginine (ADMA) in Chronic Kidney Disease, Current Enzyme Inhibition 2007; 3 (4) . https://dx.doi.org/10.2174/157340807782330200
DOI https://dx.doi.org/10.2174/157340807782330200 |
Print ISSN 1573-4080 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6662 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Role of Lysophosphatidylcholine (LPC) in Atherosclerosis
Current Medicinal Chemistry Cellular Mechanisms of the Protective Effect of Polyphenols on the Neurovascular Unit in Strokes
Cardiovascular & Hematological Agents in Medicinal Chemistry Cardiovascular Pharmacogenomics
Current Pharmacogenomics and Personalized Medicine Research and Clinical Applications of Optical Coherence Tomography in Invasive Cardiology: A Review
Current Cardiology Reviews Insulin Treatment and Weight Gain in Type 2 Diabetes: Is Our Knowledge Complete?
Current Nutrition & Food Science Interconnection of Estrogen/Testosterone Metabolism and Mevalonate Pathway in Breast and Prostate Cancers
Current Molecular Pharmacology Anti-Inflammatory Drugs in Psychiatry
Inflammation & Allergy - Drug Targets (Discontinued) Follistatin-like 1 in Cardiovascular Disease and Inflammation
Mini-Reviews in Medicinal Chemistry Directions for Enhancement of the Therapeutic Efficacy of Mesenchymal Stem Cells in Different Neurodegenerative and Cardiovascular Diseases: Current Status and Future Perspectives
Current Stem Cell Research & Therapy Alzheimer Disease and Type 2 Diabetes Mellitus: The Link to Tyrosine Hydroxylase and Probable Nutritional Strategies
CNS & Neurological Disorders - Drug Targets Milestones in Antihypertensive Drug Treatment
Current Pharmaceutical Design Non-invasive Estimation of Aortic Blood Pressures: A Close Look at Current Devices and Methods
Current Pharmaceutical Design Current Management of Intermittent Claudication: The Role of Pharmacological and Nonpharmacological Symptom-Directed Therapies
Current Vascular Pharmacology Drotrecogin Alfa (Activated) in the Treatment of Severe Sepsis
Current Drug Safety Inflammation in Ischemic Stroke: Mechanisms, Consequences and Possible Drug Targets
CNS & Neurological Disorders - Drug Targets Endothelial Dysfunction in the Hypertensive State: Mechanisms of Hypertensive Cardiovascular Complications
Current Hypertension Reviews Acute Respiratory Failure in Obstetric Patients
Current Women`s Health Reviews Micro RNA: An Epigenetic Regulator of Type 2 Diabetes
MicroRNA Does Caffeine Affect Cardiovascular Responses?
Vascular Disease Prevention (Discontinued) Vascular Inflammation During Human Rickettsioses: An Essential Host Response and a Potential Target for Supplemental Therapy
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry